Reby Advisors’s Pfizer PFE Stock Holding History

Reby Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$487K	Buy	+13,217	New	+$485K	0.13%	39

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Reby Advisors's PFE Position: Q4 2020 in Review

Reby Advisors opened a new position in Pfizer (PFE) in Q4 2020: 13,217 shares worth $487K. The stake represents 0.13% of the portfolio and ranks #39 among its holdings.

2,674 funds tracked by Wall St. Rank hold PFE as of Q4 2020.

Reby Advisors held 13,217 shares of Pfizer worth $487K as of Q4 2020.
Pfizer was a new Reby Advisors position in Q4 2020.
Pfizer made up 0.13% of Reby Advisors's portfolio in Q4 2020, its #39 holding.
2,674 funds tracked by Wall St. Rank held Pfizer as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.